Quoin pharmaceuticals announces fda clearance of ind for its lead asset, qrx003, for netherton syndrome

Quoin will initiate clinical testing in 1h 2022 quoin will initiate clinical testing in 1h 2022
QNRX Ratings Summary
QNRX Quant Ranking